---
document_datetime: 2025-03-20 15:44:00
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/constella-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: constella-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.9771671
conversion_datetime: 2025-12-28 03:15:49.701236
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Constella

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                            |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10025 /202408  | Periodic Safety Update EU Single assessment - linaclotide                                                                                       | 13/03/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                  |
| II/0063              | Update of section 4.4 of the SmPC in order to remove the statement relating to guanylate cyclase- C (GCC) receptor expression in the paediatric | 05/09/2024                          |                                             | SmPC, Annex II, Labelling and PL | Update of section 4.4 of the SmPC in order to remove the statement relating to guanylate cyclase-C (GCC) receptor expression in the paediatric population based on |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | population based on final results from study MCP- 103-311; this is a non-interventional clinical research study to characterize GCC mRNA expression in duodenal and colonic mucosal biopsies in children aged 0 to 17 years. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information and to bring it in line with the latest QRD template. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     |                 | Final results from study MCP-103-311, a non-interventional clinical research study to characterize GCC mRNA expression in duodenal and colonic mucosal biopsies in children aged 0 to 17 years, have been submitted. As a consequence, section 4.4 of the SmPC has been updated to remove the information regarding the paediatric population.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0064           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                           | 26/08/2024 |     | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                  |
| IB/0062             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                    | 11/06/2024 | n/a |                 |                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10025 /202308 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/04/2024 | n/a |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                |
| IAIN/0061/G         | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved                                                                                                                                                                                                                                                             | 05/04/2024 | n/a |                 |                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                              |            |            |                        |                                                                                                                                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10025 /202208 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                | 16/03/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                               |
| N/0058              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                         | 18/07/2022 |            | PL                     |                                                                                                                                                                                                                                                 |
| T/0057              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                      | 29/04/2022 | 07/06/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                 |
| PSUSA/10025 /202108 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                | 07/04/2022 |            | SmPC and PL            | PRAC Recommendation - maintenance                                                                                                                                                                                                               |
| IA/0055             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                            | 27/05/2021 | n/a        |                        |                                                                                                                                                                                                                                                 |
| IB/0054/G           | This was an application for a group of variations. B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.a.3.b.6 - Changes in the composition (excipients) of the finished product - Other excipients | 19/05/2021 | 22/09/2021 | SmPC and PL            | The product information was updated to add 'Polyethylene glycol' in section 6.1 of the Summary of Product Characteristics and section 6 of the Package Leaflet. In addition the German local representative was updated in the package leaflet. |

<div style=\"page-break-after: always\"></div>

|                     | comparable excipient with the same functional characteristics and at a similar level                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0053             | Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on intestinal perforation and to add gastrointestinal perforation to the list of adverse drug reactions (ADRs) with frequency rare as requested by the PRAC in procedure EMEA/H/C/002490/LEG/015, the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 09/04/2021 | 22/09/2021 | SmPC and PL | Of the provided 13 ICSR forms of the cumulative cases of intestinal perforation seven were considered possibly related to linaclotide, for one case a causal relationship could not be excluded but data were lacking for a proper assessment, four were not assessable due to lack of information, and for two cases it was not quite clear whether they are cases at all as it was uncertain if intestinal perforation happened at all under treatment. It was considered that linaclotide, due to its mechanism of action inducing movement of the intestine and based on the course of the events which, in some of the provided case reports, suggested a temporal relation could be a trigger for intestinal perforation in patients with localized or diffuse weakness of the intestinal wall. These patients should be advised to seek immediate medical care in case of severe, persistent or worsening abdominal pain and linaclotide should be discontinued if these symptoms occur. For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10025 /202008 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/04/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0051             | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/10/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0049             | Update of section 4.6 of the SmP based on the final results of Lactation study 1915-7/LIN-PK-01 listed as                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 04/09/2020 | 22/09/2021 | SmPC and PL | In Study LIN-PK-01 linaclotide and its active metabolite (MM-419447) were below the quantitation limit in the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | a category 3 study in the RMP; this is a an open- label, multiple-dose, milk-only lactation study in lactating women receiving linaclotide therapeutically. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                |            |            |             | breast milk of lactating women studied. Given the minimal/negligible oral bioavailability of linaclotide, the large molecular size of linaclotide and its metabolite it is reasonable to conclude, that breastfed infants do not receive linaclotide or its metabolite through breast milk and therefore, no pharmacological activity of linaclotide and its metabolite are expected in breastfed infants. Constella can be used during breast-feeding.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0050             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                            | 20/08/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0048             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                   | 04/06/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10025 /201908 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                                                                                                                                | 26/03/2020 | 02/06/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10025/201908.                                                                                                                                                                                                                                                                                                                |
| IB/0046/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 07/05/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                     |            |     | manufacturer   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| IB/0045/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 30/04/2020 | n/a |                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| intermediate used in the manufacturer of a novel A.7 - Administrative change manufacturing sites A.7 - Administrative change manufacturing sites B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.2.e - Changes in the AS - Minor change ASMF B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.b.2.b - Change in test starting material/reagent/intermediate a test procedure for the material/reagent/intermediate, procedure is already authorised B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0047 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                      | 23/04/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0043 | Submission of the final report from study 'Linaclotide Utilization Study in Selected European Populations' listed as a category 3 study in the RMP. This is a rug Utilisation Study (DUS) addressing the following safety concerns: - The potential for off-label use and abuse/excessive use - Extent of use in pregnancy and lactation, and male patients - Assess the extent of off-label use and the extent of use in males and in pregnant females C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 12/03/2020 | n/a | In the study the potential off-label use in patients diagnosed with IBS was high with regard to abuse or excessive use in two of the three countries. On the other hand, the majority of patients either switched or discontinued treatment. Discontinuation occurred mainly after the first prescription and discontinuation might be a consequence of diarrhoea development. Accordingly, no additional risk minimisation measures are recommended at this point in time due to the self-limiting (trial and error) nature of the off-label use. The study results indicate that linaclotide is prescribed only very rarely to pregnant women ( Ë‚ 0.5% in all countries) and with regard to lactation it was not possible to identify cases, as there are no diagnostic codes specific for this in use. Males accounted for 13.7%, 14.3% and 18.9% users in the UK, Spain, and Sweden respectively. The gender distribution of linaclotide users appears to match the |
| IB/0042 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 23/04/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IAIN/0041           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                 | 10/04/2019   | n/a        |                 |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| N/0040              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                       | 21/03/2019   | 02/06/2020 | PL              |                                   |
| PSUSA/10025 /201808 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                                                                                              | 14/03/2019   | n/a        |                 | PRAC Recommendation - maintenance |
| IA/0038             | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                         | 23/08/2018   | n/a        |                 |                                   |
| IB/0037/G           | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data | 17/04/2018   | 07/06/2018 | Annex II and PL |                                   |
| PSUSA/10025 /201708 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                                                                                              | 08/03/2018   | n/a        |                 | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0036           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                        | 21/12/2017   | 07/06/2018   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                         |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0034             | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                    | 15/09/2017   | n/a          |                          |                                                                                                                                                                                                                                                                         |
| R/0032              | Renewal of the marketing authorisation.                                                                                                                                                                           | 22/06/2017   | 28/08/2017   | SmPC, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Constella in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0033             | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                                       | 05/07/2017   | 07/06/2018   | SmPC                     |                                                                                                                                                                                                                                                                         |
| PSUSA/10025 /201608 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                         | 09/03/2017   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| IB/0031             | B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test                                                                         | 16/02/2017   | n/a          |                          |                                                                                                                                                                                                                                                                         |
| II/0028             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                             | 27/10/2016   | n/a          |                          |                                                                                                                                                                                                                                                                         |
| N/0029              | Update of the package leaflet to remove the telephone number of the Marketing Authorisation Holder in Section 6. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 06/09/2016   | 11/04/2017   | PL                       |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0027             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                  | 25/08/2016   | 11/04/2017   | SmPC, Labelling and PL   |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0026             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                        | 22/06/2016   | n/a          |                          |                                                                                                                                            |
| PSUSA/10025 /201508 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                            | 01/04/2016   | 26/05/2016   | SmPC and PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10025/201508. |
| IAIN/0025/G         | This was an application for a group of variations. A.z - Administrative change - Other variation A.1 - Administrative change - Change in the name and/or address of the MAH                                          | 22/04/2016   | 11/04/2017   | SmPC, Labelling and PL   |                                                                                                                                            |
| T/0024              | Transfer of Marketing Authorisation                                                                                                                                                                                  | 20/01/2016   | 22/02/2016   | SmPC, Labelling and PL   |                                                                                                                                            |
| II/0021             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                    | 25/06/2015   | 22/02/2016   | SmPC, Annex II and PL    |                                                                                                                                            |
| IB/0022/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time | 10/04/2015   | n/a          |                          |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | data B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0017             | Introduction of a new manufacturer of the active substance that is supported by an ASMF B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                           | 26/03/2015 | n/a |                                   |
| PSUSA/10025 /201408 | Periodic Safety Update EU Single assessment - linaclotide                                                                                                                                                                                                                                                                                            | 12/03/2015 | n/a | PRAC Recommendation - maintenance |
| IA/0018             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                              | 11/12/2014 | n/a |                                   |
| PSUV/0016           | Periodic Safety Update                                                                                                                                                                                                                                                                                                                               | 11/09/2014 | n/a | PRAC Recommendation - maintenance |
| II/0013/G           | This was an application for a group of variations. This was an application for a group of variations: Addition of a manufacturing site for the finished product including primary and secondary packaging, batch control/testing. Furthermore, a change in the                                                                                       | 24/07/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| batch size of the finished the manufacturing process and a change in the specification limits of the finished product. B.II.b.1.c - Replacement manufacturing site for the manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.1.b - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.II.b.4.d - Change in the size ranges) of the finished relates to all other pharmaceutical manufactured by complex B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.d.1.g - Change in the and/or limits of the finished   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | product) of a specification parameter wit its corresponding test method as a result of a safety or quality issue                                                                                                                                                                                                                               |            |            |                 |                                                                                                                                                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014/G | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 04/07/2014 | n/a        |                 |                                                                                                                                                               |
| PSUV/0010 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                         | 13/06/2014 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                             |
| IAIN/0015 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                     | 23/05/2014 | 16/03/2015 | Annex II and PL |                                                                                                                                                               |
| IB/0011   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                      | 14/03/2014 | 16/03/2015 | SmPC            |                                                                                                                                                               |
| IA/0012   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                   | 12/03/2014 | n/a        |                 |                                                                                                                                                               |
| PSUV/0009 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                         | 18/12/2013 | 20/02/2014 | SmPC and PL     | Please refer to Constella-H-C-2490-PSUV-0009 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IB/0008/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                             | 08/01/2014 | n/a        |                 |                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or   |            |            |      | quality issue   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------|
| IA/0007   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/11/2013 | 20/02/2014 | SmPC |                 |
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/10/2013 | 20/02/2014 | PL   |                 |
| II/0003/G | This was an application for a group of variations. Group of a type II variation to introduce a new manufacturer of the active substance and a subsequent type IA variation to introduce a new residual solvents testing site.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/09/2013 | n/a        |      |                 |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is supported by an ASMF B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   |            |            |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IAIN/0005 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                              | 02/08/2013 | 20/02/2014 | SmPC and PL |
| IA/0004/G | This was an application for a group of variations. B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                                                        | 06/06/2013 | n/a        |             |
| IB/0002/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                               | 04/04/2013 | n/a        |             |

<div style=\"page-break-after: always\"></div>

|        | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of manufacturing sites   |            |            |    |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| N/0001 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                               | 01/03/2013 | 20/02/2014 | PL |